International consensus guidance for management of myasthenia gravis: Executive summary

Neurology

Volumn 87, Issue 4, 2016, Pages 419-425

  Sanders, Donald B ^a   Wolfe, Gil I ^b   Benatar, Michael ^c   Evoli, Amelia ^d   Gilhus, Nils E ^e   Illa, Isabel ^f,g   Kuntz, Nancy ^h   Massey, Janice M ^a   Melms, Arthur ⁱ   Murai, Hiroyuki ^j,k   Nicolle, Michael ^l   Palace, Jacqueline ^m   Richman, David P ⁿ   Verschuuren, Jan ^o   Narayanaswami, Pushpa ^p  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k KYUSHU UNIVERSITY   (Japan)

^l UNIVERSITY OF WESTERN ONTARIO   (Canada)

^m JOHN RADCLIFFE HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; CORTICOSTEROID; IMMUNOGLOBULIN; PREDNISONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

BULBAR PARALYSIS; CONSENSUS; DISEASE DURATION; DYSPNEA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; REMISSION; RESPIRATORY FAILURE; REVIEW; THYMECTOMY; TREATMENT DURATION; ADULT; CHILD; FEMALE; MOTIVATION; PLASMA EXCHANGE;

ADULT; CHILD; CONSENSUS; FEMALE; GOALS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; PLASMA EXCHANGE; PREGNANCY; THYMECTOMY;

EID: 84980368667     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002790     Document Type: Review

References (12)

1. Deenen JCW, Horlings CGC, Verschuuren JJGM, Verbeek ALM. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis 2015;2:73-85
2. Grob D, Brunner NG, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149
3. Jaretzki A, Barohn RB, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23
4. Wiendl H. Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms [online]. Available at: http://www.dgn.org/leitlinien/11-leitlinien-der-dgn/3005-ll-68-ll-diagnostik-und-therapie-der-myasthenia-gravis-unddes-lambert-eaton-syndroms. Accessed August 14, 2015
5. Fuhr P, Gold R, Hohlfeld R, et al. Diagnostik und therapie der myasthenia gravis und des Lambert-Eaton Syndroms. In: Diener HC, Weimar C, Deuschl G, et al, eds. Leitlinien für Diagnostik und Therapie in der Neurologie, 5th ed. Stuttgart: Thieme; 2012:830-856
6. Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol 2015;6:21-31
7. Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: association of British Neurologists' management guidelines. Pract Neurol 2015; 15:199-206
8. Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 2014;85: 538-543
9. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902
10. Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA: RAND Corporation; 2001
11. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 [online]. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed May 25, 2016
12. US Food and Drug Administration. Pregnancy and Lactation Final Rule [online]. Available at: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ Labeling/ucm093307.htm. Accessed November 11, 2015